42 results about "Autoimmune antibody" patented technology

The present invention relates to the preparation of a cell slide assembly for a CBA kit for detecting MOG-IgG, the CBA detection kit and its application. The preparation method of the cell slide assembly is as follows: S1: construction of MOG plasmid; S2: overexpression of MOG gene Lentiviral packaging; S3: Construction of a cell line (MOG-293T cell line) overexpressing the MOG gene; S4: Preparation of cell slide components. The kit includes cell slide assembly, anti-human IgG-FITC secondary antibody, blocking solution, PBS and mounting medium; the kit can be used for detection of MOG autoimmune IgG antibody in clinical samples. The kit of the invention has the advantages of simple operation, strong detection specificity, high sensitivity, good repeatability of experimental results, can be popularized and applied, and can be used for detection of MOG autoimmune IgG antibody in clinical samples.

Methods are described for detection of autoimmune antibodies against the TSH receptor using TSH receptor chimeras, which preferably only contain the extracellular portion of the TSH wild type receptor modified as chimera, and are modified by highly immunogenic peptide residues or by enzymes suitable for detection, wherein the determination methods described allow simple detection of stimulating, blocking and neutral autoimmune antibodies.

The invention provides a kit and method for detecting an autoimmune antibody of the type-I diabetes mellitus and belongs to the technical field of biochemical medicine detection. The method comprises the following steps of: adding a luciferase as an antibody fusion protein, wherein the luciferase as the antibody fusion protein is generated by 293 cell culture and can be specifically combined with a diabetes mellitus autoantibody in serum of a patient; then, adding protein-A agarose, depositing a fusion protein as an antibody compound, centrifuging, and then, absorbing the uncombined fusion protein from a supernatant liquid; and then, adding a luciferase substrate, and detecting the fluorescence intensity by using a fluorescence detection instrument to finally measure the content of the diabetes mellitus autoantibody in a sample to be detected. Compared with the traditional HPLC (High Performance Liquid Chromatography), a micro-quantitative fluorescence detection instrument used for detecting in the method has the advantages of simplicity in operation, no need of uncovering to block a pollution way, high sensitivity and signal to noise ratio, stable and reliable measured value and capability of ensuring reliable experiment result and safety of operating personnel and meeting the requirements of micro quantity and regent saving.

This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for both pemphigus vulgaris and pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody.

The detection of parietal cell autoimmune antibodies comprising an ATP4A D3.2 subdomain binding site can diagnose autoimmune body gastritis and/or pernicious anemia with extraordinary sensitivity and specificity that is far superior to existing commercial assays. Further, the assay has diagnostic applications for use in diagnosing type 1 diabetes, thyroiditis and Addison's disease. As pernicious anemia is typically a disease of the elderly, detection of parietal cell antibodies may precede clinical disease by many years if not decades, thereby allowing the initiation of therapeutic interventions such as vitamin B12 administration to prevent the development of pernicious anemia or immunologic interventions to prevent type 1 diabetes and its complications.

The present invention relates to methods for detecting antibodies, methods for diagnosing lung cancer and kits for lung cancer diagnosis. The methods of the invention are based on a blood or serum sample of a subject. According to a preferred embodiment, the invention uses a combination of different peptides comprising an amino acid stretch of BARD1, short peptides and/or larger fragments thereof. In preferred embodiments, the methods of the invention comprise measuring the amount of autoimmune antibodies in the sample binding to each of the different peptides and applying a statistically determined assessment for making the diagnosis.

The invention discloses an antigen-immobilized matrix membrane, a kit comprising the same for detecting an antinuclear antibody spectrum related to autoimmune diseases and purpose thereof. The antigen-immobilized matrix membrane comprises but not only comprises following 22 mutually independent antigen detection lines including double-stranded DNA, histone, ribosome P0 protein, PCNA, SmD1, SmD3, SmB/B', snRNP-A, snRNP-C, snRNP68/70, SSA/Ro60, SSA/Ro52, SSB/La, Jo-1, PL-7, PL-12, PmScl, Scl-70, CENP-A, CENP-B, RA33 and PR3. When the kit containing the antigen-immobilized matrix membrane is usedfor detection, 22 kinds of autoimmune antibodies can be detected simultaneously; and thus diagnosis of eight kinds of common diffuse connective tissue diseases is assisted.

The invention belongs to the technical field of immunodetection, and discloses a treatment method for reducing non-specific adsorption in autoimmune antibody detection and a kit thereof. The kit for reducing detection of the autoimmune antibody, provided by the invention, is formed by combining polymer particles, a magnetic particle coupling antigen, AP-labeled anti-human IgG, an autoantibody IgGantibody and a Tris buffer solution after mutual dissolution. According to the detection kit for reducing the autoimmune antibody, polymer particles and magnetic particles in the kit are added to competitively bind non-specific substances to a detection target object; the non-specific adsorption capacity of the magnetic beads on the surfaces of the magnetic particles is further reduced; the falsepositive probability of the detection kit caused by non-specific adsorption in the autoimmune antibody detection process is remarkably reduced, the influence of non-specific substances on a clinical sample test result is weakened, and the detection rate of the detection kit and the effectiveness and stability of the detection result are improved.

The invention relates to a kit. The kit adopts a gene recombinant Renilla and multi-antigen fusion protein to detect an autoimmune antibody in serum, which is related to the breast cancer, has high sensitivity and specificity, provides basis for diagnosis of the breast cancer, and provides scanning conditions for further pathological diagnosis. The kit is rapid and convenient to detect, accurate in detection result and harmless for a patient, has no radio-immunity pollution, can meet requirements of clinical diagnosis and particularly requirements of primary health care institutions and community general practitioners, and has wide market prospect.

The invention relates to a polypeptide combined with an immune antibody. Three arginine side chains in sequences of the polypeptide are modified to be electrically neutral or electronegative amino acid; and two non-adjacent cysteine side chain mercapto groups on the polypeptide sequences forms annular disulfide bonds. The polypeptide can be combined with the autoimmune antibody of rheumatoid arthritis and can have high affinity to HLA-DR. The experimental result shows that the specificity of the polypeptide combined with the autoimmune antibody of the rheumatoid arthritis is over 75 percent. Compared with the like products sold in the market, the polypeptide has the advantage that: the sensitivity of the polypeptide is obviously improved so as to more contribute to the detection in vitro for the autoimmune antibody of the rheumatoid arthritis.

The invention provides a treatment method for reducing nonspecific adsorption of magnetic beads in autoimmune antibody detection. The treatment method comprises the following steps of: 1, preparing a magnetic bead working solution; 2, adding newborn calf serum into the prepared magnetic bead working solution; 3, uniformly mixing the magnetic bead working solution added with the newborn calf serum at room temperature, and carrying out reaction; 4, cleaning the magnetic bead working solution after reaction with newborn calf serum, standing and separating, and repreparing according to the concentration of 0.3 mg/ml; and 5, detecting an anti-myeloperoxidase immunoglobulin G antibody by adopting the magnetic bead working solution prepared after the new-born calf serum is added and treated in the above steps. According to the treatment method, animal serum is added into the magnetic bead working solution to be combined with non-specific substances, so that the non-specific adsorption capacity of magnetic particles is reduced, false positive results caused by non-specific adsorption in the detection process are remarkably reduced, and the detection sensitivity and specificity are effectively improved.

The invention discloses a medicinal composition for treating multiple sclerosis, and the medicinal composition comprises BAFF (B cell activating factor belonging to TNF family) inhibitor (TACI-IgG) and IL-15 inhibitor (anti IL-15 antibody). The medicinal composition is used for treating a murine model EAE (experimental allergic encephalomyelitis) mice subjected to the multiple sclerosis, and the results showed that the medicinal composition can significantly reduce the number of B cells, helper T cells and memory B / T cells in spleen and lymph nodes, inhibits the production of activation and autoimmune antibodies of the B cells, and relieves clinical autoimmune symptoms. The medicinal composition is effective in the treatment of the multiple sclerosis.

Provided herein are synthetic peptides, methods and kits for easy detecting or diagnosing an autoimmune disease, particularly, Henoch-Schönlein purpura (HSP), based on the detection of autoimmune antibodies with peptides derived from β-2-glycoprotein-1 (β2-GPI).

This disclosure provides methods and compositions for treating TTP based on transfusion of a relatively small number of genetically modified red blood cells. The genetically modified red blood cells express a fusion protein including a fragment of ADAMTS13 that is enzymatically active against von Willebrand factor (VWF). The fragments of ADAMTS13 can be resistant to the inhibitors, e.g., the auto-immune antibodies, which are responsible for the acquired form of TTP.